Researchers from the University of Sheffield and the University of Manchester have found C. diff is able to evolve high levels of vancomycin resistance very quickly—in less than two months the ...

Additionally, rifaximin is considered a follow-up therapy after vancomycin, particularly in patients with multiple recurrences. Bezlotoxumab, an IgG1 monoclonal antibody targeting C. difficile ...

Unfortunately, only three antibiotics are available to treat C. difficile infections. The drug of choice for most patients is vancomycin, but in about one-third of patients, their infection ...

difficile toxin by enzyme immunoassay or cell cytotoxicity assay who had been treated with metronidazole or vancomycin for less ... CDI (e.g., fever ≥ 37.7 °C, abdominal pain, elevated WBC ...

difficile. Now, they report success using tigecycline to treat four patients with severe C. difficile infection ... three had failed metronidazole and vancomycin and were being considered for ...

Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

The pathogen C. diff - the most common cause of health care-associated infectious diarrhea - can use a compound that kills ...

Researchers from the University of Sheffield and the University of Manchester have found C. diff is able to evolve high levels of vancomycin resistance very quickly - in less than two months the ...